On-Demand CME Videos
Strategies to Alleviate the Multidimensional Burden of Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Online CME Activity
To learn the right answer to the following question, click "Start Activity"!
Francesca is a 10 year old with a history of atopic dermatitis since childhood. While in gym class she has noticed that she is smaller than her peers and is last to get picked when choosing teams for sports like basketball. Which of the following is most likely to play a role in her shorter stature in comparison to her peers?
a. Increased pro-inflammatory cytokines
b. Poor sleep quality
c. Microbiome dysbiosis at the level of the skin
d. Barrier dysfunction at the level of the skin
This activity was recorded at the Winter Clinical Dermatology Conference-Hawaii and is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
March 20, 2023
March 20, 2024
At the completion of this activity, participants should be better able to:
Underline the multidimensional burden of moderate-to-severe atopic dermatitis in children and adolescents
Recall the multidimensional benefits of systemic biologics for the management of moderate-to-severe atopic dermatitis in children and adolescents
Discuss seamless integration of biologics into daily clinical practice through enhanced multidisciplinary care
Alexandra Golant, MD
Medical Director, Dermatology Faculty Practice
Associate Director, Residency Program
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Mona Shahriari, MD
Central CT Dermatology
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Consultant: Regeneron, Sanofi, Lilly, Incyte, Dermavant, Arcutis, LEO Pharma, Janssen
Speakers’ Bureau or Honoraria: Regeneron, Sanofi, Lilly, Incyte, Dermavant, Arcutis
Grant/Research Support: AbbVie, Dermira, Cara, Dermavant, Novartis, Union
Consultant: Abbvie, BMS, Dermavant, Leo, Lilly, Sanofi, Regeneron, UCB
Speakers’ Bureau or Honoraria: Abbvie, BMS, Lilly, Leo, Janssen, Dermavant
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.